Original posting date – May 22, 2013 – St. Louis, MO
St. Louis-based GeneriCo LLC is in the middle of a $2.5 million fundraising round, according to a recent filing with the U.S. Securities and Exchange Commission (SEC).
Generico develops and markets generic pharmaceuticals. It focuses on generics that have been neglected by mid and large generic companies and also have an embedded drug delivery technology making the formulation challenging and economically not appealing to middle and large competitors, and too complex for tightly focused small generic companies.
The pharmaceutical company is led by President and CEO Thomas Brya.
Brya spent four years at KV Pharmaceutical and currently also leads biotech company AcuPlaq LLC and serves as an executive in residence consultant for BioGenerator. AcuPlaq is focused on advancing a proprietary nano-emulsion drug complex developed by Washington University cardiovascular researcher Dr. Samuel Wickline.